Tuesday, March 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Next Generation Diagnostics System for CBRN Threats

by Global Biodefense Staff
May 14, 2012

An updated timeline for the Next Generation Diagnostics System (NGDS) acquisition program was announced by the U.S. Army last week, shifting the estimated release of a formal Request for Proposals (RFP) to sometime within the next 20 days.

The NGDS effort, spearheaded by the Joint Project Manager for Chemical Biological Medical Systems (JPM CBMS), is intended to develop, test and field a portable human diagnostic system for Chemical, Biological, Radiological, and Nuclear (CBRN) threats and emerging threats of concern. Such a deployable component system is intended to eventually replace and improve upon the current Joint Biological Agent Identification and Diagnostic System (JBAIDS).

The government anticipates that three contracts will be awarded for the procurement for the competitive prototyping stage requirements. Upon completion of the competitive prototyping stage, the Government anticipates conducting a down select which will result in one contract taking the contractor through the remainder of the development phases to FDA clearance.

The NGDS candidates selected for initial award must either be currently under clinical evaluation as an in vitro device (IVD) for the U.S. market; be cleared via a 510(k) or Premarket Approval (PMA) by the FDA as an IVD or submitted for clearance or approval; or have received approval by the European Medicines Agency (EMA) as an IVD. The contractual intent is to for the system to be FDA cleared for threat diagnostics at the time of fielding.

The contract is anticipated to be a 10-year effort with a base period of approximately nine months and nine one year option periods. The guaranteed minimum order will be the negotiated value of the first delivery order, and the cumulative total of all delivery orders awarded to all awardees will not exceed $250,000,000.00 over the life of the contract.

Full details are available under Solicitation Number is W911QY-12-R-0021. The government anticipates proposals will be due 45 days after the RFP is released. Notes and supporting materials from the NGDS Industry Day held in April are available at the Natick Contracting Division website.

Tags: JPEO-CBRNDPOC DiagnosticsRequest for Proposals

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
Killing Anthrax More Quickly with Hot Air Decontamination
CBRNE

Killing Anthrax More Quickly with Hot Air Decontamination

January 4, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC